Online citations, reference lists, and bibliographies.

Novel Endoscopic Diagnosis For Bladder Cancer

S. Lerner, A. Goh
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Advances in endoscopic imaging technology may improve sensitivity for the detection of bladder cancer and provide a more complete understanding of the urothelial landscape, and it also may lead to improved short‐term and long‐term cancer control. Fluorescence cystoscopy requires intravesical administration of a photosensitizing agent (5‐aminolevulinic acid or hexaminolevulinate), and imaging with a blue‐light endoscopy system demonstrably improves the detection of papillary and flat bladder lesions compared with conventional white‐light cystoscopy. Prospective phase 3 clinical trials have demonstrated improved diagnostic ability, enhanced tumor resection, and a small but significant reduction in recurrence‐free survival. Optical coherence tomography delineates subsurface microarchitecture information about bladder lesions in real time and has the ability to discriminate between noninvasive and invasive cancers. Narrow‐band imaging may augment white‐light cystoscopy by providing increased contrast between normal and abnormal tissue on the basis of neovascularity. Confocal laser endoscopy has been applied to the urinary tract using thinner probes adapted from use in gastrointestinal malignancies and provides exquisite images at microscopic resolution. More technology is on the horizon that may further enhance our ability to detect and accurately stage bladder tumors and distinguish benign from malignant or dysplastic lesions. Cancer 2015;121:169–78. © 2014 American Cancer Society.
This paper references
adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder
(2009)
10.1117/1.2981827
Endoscopic image analysis of photosensitizer fluorescence as a promising noninvasive approach for pathological grading of bladder cancer in situ.
J. Kah (2008)
10.1111/j.1751-1097.2008.00384.x
Fluorescence diagnosis of bladder cancer with new water soluble hypericin bound to polyvinylpyrrolidone: PVP-hypericin.
A. Kubin (2008)
10.1016/j.eururo.2013.06.003
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
M. Babjuk (2013)
10.1111/j.1464-410X.2008.07846.x
A comparison of white‐light cystoscopy and narrow‐band imaging cystoscopy to detect bladder tumour recurrences
H. Herr (2008)
10.1111/j.1464-410X.2011.10374.x
Treatment changes and long‐term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non‐muscle‐invasive bladder cancer (NMIBC)?
B. Geavlete (2012)
10.1117/1.3512206
Quantitative measurement of attenuation coefficients of bladder biopsies using optical coherence tomography for grading urothelial carcinoma of the bladder.
E. Cauberg (2010)
10.1117/1.3171943
Wavelet analysis enables system-independent texture analysis of optical coherence tomography images.
Colleen A. Lingley-Papadopoulos (2009)
10.1097/01.JU.0000100480.70769.0E
Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy.
J. Schmidbauer (2004)
10.1016/j.urology.2012.06.035
Confocal laser endomicroscopy of bladder tumors associated with photodynamic diagnosis: an ex vivo pilot study.
J. Bonnal (2012)
10.1007/s00280-010-1375-0
Biodistribution of PVP-hypericin and hexaminolevulinate-induced PpIX in normal and orthotopic tumor-bearing rat urinary bladder
Joachim Vandepitte (2010)
with 5 - aminolevulinic acid - induced fluorescence cystoscopy : a multicenter randomized , double - blind , placebo - controlled trial
G Mowatt (2011)
10.1016/J.JURO.2007.03.028
A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.
Y. Fradet (2007)
10.1016/j.juro.2011.10.131
Early detection of carcinoma in situ of the bladder: a comparative study of white light cystoscopy, narrow band imaging, 5-ALA fluorescence cystoscopy and 3-dimensional optical coherence tomography.
H. Ren (2012)
10.1111/j.1464-410X.2004.05715.x
5‐aminolaevulinic acid‐induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer
M. Babjuk (2005)
10.1111/j.1464-410X.2005.05508.x
Is photodynamic diagnosis using hypericin better than white‐light cystoscopy for detecting superficial bladder carcinoma?
H. G. Sim (2005)
10.1097/01.JU.0000180413.98752.A1
Fluorescence guided optical coherence tomography for the diagnosis of early bladder cancer in a rat model.
Z. Wang (2005)
10.1046/j.1464-410X.2002.02690.x
Hypericin‐based fluorescence diagnosis of bladder carcinoma
M. D'Hallewin (2002)
EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder: update
M Babjuk (2013)
10.1016/S0022-5347(05)67975-X
Multivariate analysis of the prognostic factors of primary superficial bladder cancer.
F. Millán-Rodríguez (2000)
10.1111/j.1464-410X.2011.10090.x
Fluorescence‐guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in T  a/T1 patients: a randomized two‐centre study
G. Hermann (2011)
10.1089/end.2012.1556
Global randomized narrow band imaging versus white light study in nonmuscle invasive bladder cancer: accession to the first milestone-enrollment of 600 patients.
S. Naito (2013)
10.4103/0970-1591.82845
Emerging optical techniques in advanced cystoscopy for bladder cancer diagnosis: A review of the current literature
C.C. Cauberg Evelyne (2011)
10.1016/S0022-5347(08)60956-8
FLUORESCENCE AND WHITE LIGHT CYSTOSCOPY FOR DETECTING CARCINOMA IN SITU OF THE BLADDER
Hao Liu (2008)
10.1007/s00345-009-0387-z
Application of new technology in bladder cancer diagnosis and treatment
A. Goh (2009)
10.1097/LGT.0b013e31825d7bf0
Cervical Epithelial Brightness by Optical Coherence Tomography Can Determine Histological Grades of Cervical Neoplasia
S. Belinson (2013)
Cancer statistics, 2013. CA Cancer
R Siegel (2013)
10.1111/j.1464-410X.2006.06144.x
The value of a second transurethral resection for T1 bladder cancer
H. Schwaibold (2006)
10.1016/J.JURO.2007.03.034
A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.
H. Grossman (2007)
10.1364/OE.18.003840
Time- and Spectral-resolved two-photon imaging of healthy bladder mucosa and carcinoma in situ.
R. Cicchi (2010)
10.1053/HUPA.2001.24999
Correlation of cystoscopic impression with histologic diagnosis of biopsy specimens of the bladder.
S. Cina (2001)
10.1016/1011-1344(93)80127-U
Porphyrins, porphyrias, cancer and photodynamic therapy--a model for carcinogenesis.
A. Batlle (1993)
10.1097/00005392-199909010-00019
Recurrence and progression in low grade papillary urothelial tumors.
S. Holmäng (1999)
10.1097/01.JU.0000169257.19841.2A
Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study.
D. Jocham (2005)
10.1016/S0022-5347(05)64833-1
Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors.
T. Filbeck (2002)
10.1097/01.JU.0000181814.73466.14
Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study.
D. Daniltchenko (2005)
10.1002/cncr.25523
Detection and clinical outcome of urinary bladder cancer with 5‐aminolevulinic acid‐induced fluorescence cystoscopy
A. Stenzl (2011)
Optical coherence tomography: an emerging technology for biomedical imaging and optical biopsy. Neoplasia
JG Fujimoto (2000)
10.2165/00019053-200321180-00003
The health economics of bladder cancer: a comprehensive review of the published literature.
M. Botteman (2003)
10.1016/S0022-5347(17)57037-8
Serial multiple-site biopsies in patients with bladder cancer.
M. Soloway (1978)
10.1007/BF02201977
Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients
H. Herr (2005)
10.1038/SJ.NEO.7900071
Optical coherence tomography: an emerging technology for biomedical imaging and optical biopsy.
J. Fujimoto (2000)
10.3310/hta14040
Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer.
G. Mowatt (2010)
10.1364/BOE.2.000915
Label-free high-resolution imaging of prostate glands and cavernous nerves using coherent anti-Stokes Raman scattering microscopy
Liang Gao (2011)
10.3322/canjclin.39.6.399
Cancer statistics
N. Dubrawsky (1989)
10.1016/j.urology.2009.06.088
Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors.
M. Burger (2009)
10.1016/j.giec.2013.03.004
Endomicroscopy and targeted imaging of gastric neoplasia.
M. Goetz (2013)
High-resolution imaging diagnosis and staging of bladder cancer: comparison between optical coherence tomography and high-frequency ultrasound [serial online
Z Yuan (2008)
10.1111/codi.12329
Meta‐analysis of confocal laser endomicroscopy for the detection of colorectal neoplasia
Y-Y Dong (2013)
10.1111/j.1464-410X.2007.07317.x
Narrow‐band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder
R. Bryan (2008)
10.1088/0031-9155/53/18/010
Contrasting properties of gold nanoparticles for optical coherence tomography: phantom, in vivo studies and Monte Carlo simulation.
E. Zagaynova (2008)
Confocal laser endomicroscopy of 52 bladder tumors associated with photodynamic diagnosis: an ex vivo pilot study
JL Bonnal (2012)
10.1016/J.UROLOGY.2005.04.009
Comparison of optical resolution with digital and standard fiberoptic cystoscopes in an in vitro model.
Sejal S Quayle (2005)
10.1016/J.JURO.2007.01.055
Bladder and upper tract urothelial cancer.
B. Konety (2007)
10.1016/j.juro.2009.06.039
Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy.
G. Sonn (2009)
10.1016/j.eururo.2013.07.007
Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.
M. Rink (2013)
10.1097/00005650-199508000-00007
Medicare Payments from Diagnosis to Death for Elderly Cancer Patients by Stage at Diagnosis
G. Riley (1995)
10.1016/j.urology.2008.02.002
Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer.
A. Goh (2008)
10.1016/j.juro.2012.03.127
New optical imaging technologies for bladder cancer: considerations and perspectives.
Jen‐Jane Liu (2012)
10.3322/caac.21166
Cancer statistics, 2013
R. Siegel (2013)
10.1016/j.eururo.2013.03.059
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
M. Burger (2013)
10.1016/1011-1344(90)85083-9
Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience.
J. C. Kennedy (1990)
10.1016/j.juro.2010.06.148
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.
A. Stenzl (2010)
10.1016/j.juro.2012.03.007
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy.
H. Grossman (2012)
10.1016/J.UROLOGY.2006.03.062
Clinical model of lifetime cost of treating bladder cancer and associated complications.
E. Avritscher (2006)
10.1016/S0022-5347(17)37779-0
Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder.
R. Klän (1991)
10.1117/1.2978059
High-resolution imaging diagnosis and staging of bladder cancer: comparison between optical coherence tomography and high-frequency ultrasound.
Z. Yuan (2008)
10.1016/S0022-5347(05)66532-9
Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?
A. Brauers (2001)
Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an Endoscopic Imaging for Bladder Cancer/Lerner and Goh Cancer
J Schmidbauer
10.1111/J.1751-1097.1995.TB09152.X
Cellular fluorescence of the endogenous photosensitizer protoporphyrin IX following exposure to 5-aminolevulinic acid.
P. Steinbach (1995)
10.1111/j.1464-410X.2012.11500.x
Narrow band imaging diagnosis of bladder cancer: systematic review and meta‐analysis
Changjian Zheng (2012)
10.1364/OL.26.001966
Endoscopic optical coherence tomography based on a microelectromechanical mirror.
Y. Pan (2001)
10.1117/1.1695563
Appearance of enhanced tissue features in narrow-band endoscopic imaging.
K. Gono (2004)
10.1016/J.EURURO.2006.05.021
Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy.
S. Shariat (2007)
10.1016/S0302-2838(02)00068-4
Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies.
M. Brausi (2002)
Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acidinduced fluorescence cystoscopy: a multicenter randomized, doubleblind, placebo-controlled trial
A Stenzl (2011)
10.1016/J.EURURO.2007.01.064
Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis.
M. Burger (2007)
10.1146/annurev.anchem.1.031207.112754
Coherent anti-stokes Raman scattering microscopy: chemical imaging for biology and medicine.
C. Evans (2008)
10.1016/j.juro.2010.05.087
Enhancing detection of bladder carcinoma in situ by 3-dimensional optical coherence tomography.
H. Ren (2010)
10.1016/j.gie.2013.09.020
In vivo endomicroscopy improves detection of Barrett's esophagus-related neoplasia: a multicenter international randomized controlled trial (with video).
M. Canto (2014)
10.1111/j.1464-410X.2010.09547.x
Reduced bladder tumour recurrence rate associated with narrow‐band imaging surveillance cystoscopy
H. Herr (2011)
The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation.
S. Garfield (2013)
Detection and clinical outcome of urinary bladder
A Stenzl
10.1007/s00345-009-0395-z
Economic aspects of bladder cancer: what are the benefits and costs?
K. D. Sievert (2009)
10.1016/j.eururo.2009.07.042
Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder.
J. Schmidbauer (2009)
10.1016/j.eururo.2009.10.030
Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study.
M. Schumacher (2010)
10.1089/END.2005.19.570
Evaluation of superficial bladder transitional-cell carcinoma by optical coherence tomography.
M. Manyak (2005)
10.1016/j.urology.2009.11.075
Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer.
E. Cauberg (2010)
10.1016/J.UROLOGY.2006.12.023
Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.
S. Denzinger (2007)



This paper is referenced by
Depletion of astrocyte elevated gene-1 suppresses tumorigenesis through inhibition of Akt activity in bladder cancer cells.
L. Zhang (2017)
Investigating a novel small molecule inhibitor of nuclear import as an anti-cancer approach
R. Chi (2016)
10.1016/j.pdpdt.2019.02.020
Acanthopanacis Cortex extract: A novel photosensitizer for head and neck squamous cell carcinoma therapy.
Shuhan Shi (2019)
10.3390/ijms19041116
BMP9 Promotes the Proliferation and Migration of Bladder Cancer Cells through Up-Regulating lncRNA UCA1
Liyao Gou (2018)
10.1097/CCO.0000000000000173
Management of noninvasive bladder cancers
John B. Eifler (2015)
10.1007/978-3-319-93339-9_7
Optical and Cross-Sectional Imaging Technologies for Bladder Cancer.
B. Kiss (2018)
Raman spectroscopy of luminal subtype and basal subtype muscle invasive bladder cancer
Di Jin (2019)
Long non-coding RNA HNF 1 AAS 1 promotes proliferation and suppresses apoptosis of bladder cancer cells through up-regulating Bcl-2
Yonghao Zhan (2017)
10.1016/j.eururo.2019.08.024
Multiparametric Cystoscopy for Detection of Bladder Cancer Using Real-time Multispectral Imaging.
M. Kriegmair (2019)
10.23937/2378-3419/1410123
The Resected Tumour Volume of the Specimen as a Marker of the Quality of the Transurethral Resection in T1 Urinary Bladder Cancer
Jahnson Staffan (2019)
10.3390/APP8122371
Combination of High-Resolution Optical Coherence Tomography and Raman Spectroscopy for Improved Staging and Grading in Bladder Cancer
Daniela Bovenkamp (2018)
Proceedings of the 3 rd Annual Albert Institute for Bladder Cancer Symposium
Thomas W. Flaiga (2017)
10.1002/cam4.1979
Hope and challenge: Precision medicine in bladder cancer
H. Su (2019)
10.1007/s00345-017-2147-9
Wide-field autofluorescence-guided TUR-B for the detection of bladder cancer: a pilot study
Maximilian C. Kriegmair (2017)
10.1177/1756287215603274
Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder
S. Di Stasi (2015)
10.1007/s40495-018-0163-0
Oxidative Stress and Bladder Cancer Carcinogenesis: Early Detection and Chemoprevention Involving Nrf2—an Integrative Approach
Constance Lay Lay Saw (2018)
10.1007/978-3-030-28599-9_14
Urologic Instrumentation: Endoscopes and Lasers
Robert Lurvey (2020)
10.1007/s11934-018-0833-9
Enhanced Endoscopy in Bladder Cancer
S. Pearce (2018)
10.1093/ejcts/ezx207
The identification of sub-centimetre nodules by near-infrared fluorescence thoracoscopic systems in pulmonary resection surgeries
Yamin Mao (2017)
10.1117/1.JBO.21.8.080901
Review of fluorescence guided surgery systems: identification of key performance capabilities beyond indocyanine green imaging
Alisha DSouza (2016)
10.3233/BLC-170111
Proceedings of the 3rd Annual Albert Institute for Bladder Cancer Research Symposium
Thomas Flaig (2017)
10.1007/S40267-017-0436-4
Hexaminolevulinate: a profile of its use with blue-light cystoscopy in the diagnosis of bladder cancer
Katherine A. Lyseng-Williamson (2017)
10.1159/000490875
Identification of Carbonic Anhydrase IX as a Novel Target for Endoscopic Molecular Imaging of Human Bladder Cancer
J. Wang (2018)
10.1016/j.pdpdt.2018.10.009
Recent advances in optical imaging technologies for the detection of bladder cancer.
Putu Angga Risky Raharja (2018)
10.1016/j.ajo.2016.06.001
Fluorescence Confocal Microscopy for Ex Vivo Diagnosis of Conjunctival Tumors: A Pilot Study.
A. Iovieno (2016)
10.2530/JSLSM.JSLSM-36_0016
5-Aminolevulinic Acid mediated Photodynamic Diagnosis with A Laser-Equipped Video Image Endoscope
Hajime Isomoto (2015)
10.1097/CCO.0000000000000278
Natural biology and management of nonmuscle invasive bladder cancer
K. Scarpato (2016)
10.1002/anie.201911859
Renal-clearable Macromolecular Reporter for Near-infrared Fluorescence Imaging of Bladder Cancer.
Kanyi Pu (2019)
10.1007/978-3-319-22864-8
The Paris system for reporting urinary cytology
D. Rosenthal (2016)
10.1080/14737140.2020.1744437
Why has the prognosis for muscle-invasive bladder cancer not significantly improved after decades of therapeutic advancements?
Takuro Goto (2020)
10.1089/END.2015.1507
Current diagnostics and follow-up for nonmuscle-invasive bladder cancer: are we "as good as it gets"?
Arum Cj (2015)
10.3233/BLC-150022
Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?
Boris Gershman (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar